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ABSTRACT 
 
Glucocorticoids have been used for decades in the treatment of ocular disorders via 
topical, periocular, and more recently intravitreal routes. However, their exact mechanisms of 
action on ocular tissues remain imperfectly understood. Fortunately, two recently approved 
intravitreal sustained-release drug delivery systems have opened new perspectives for these 
very potent drugs. To date, among other retinal conditions their label includes diabetic 
macular edema, for which a long-lasting therapeutic effect has been demonstrated both 
morphologically and functionally in several randomized clinical trials. The rate of ocular 
complications of intravitreal sustained-release steroids, mainly cataract formation and 
intraocular pressure elevation, is higher than with anti-vascular endothelial growth factor 
agents. Yet, a better understanding of the mechanisms underlying these adverse effects, and 
the search for the minimal efficient dose should help optimize their therapeutic window. 
 
 
INTRODUCTION 
 
Systemic glucocorticoids must be administered with caution to diabetic patients because 
they alter the glycemic homeostasis [1,2] inducing peripheral insulin resistance[3] together 
with a progressive failure of pancreatic βcells[4]. Through binding to the vascular and kidney 
mineralocorticoid receptor, they favor hypertension [5,6],[7,8] further increasing the 
metabolic and cardiovascular risk factors of the diabetic patients .[9] Yet, intraocular 
corticosteroids are paradoxically gaining momentum in the local ocular treatment of diabetic 
macular edema.[10] The eye being a confined environment, isolated from the systemic 
circulation by blood-ocular barriers, no significant systemic diffusion of corticosteroids is 
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measured following their local administration in the vitreous, preventing from the systemic 
complications of glucocorticoids. Classically, the corticosteroid family is classified by the 
potency, the mineralocorticoid-binding affinity and the half-life of each molecule. Yet, these 
classifications are translated from systemic to ocular use without evidence that the drugs 
maintain their pharmacologic properties in the eye, which questions the relevance of such 
translations. For instance, the mineralocorticoid pathway activation in the eye is not taken into 
account and the rate of specific ocular side effects, such as ocular hypertension, glaucoma and 
cataract are not included in the classification. The anti-edematous mechanisms triggered by 
glucocorticoids in the macula are complex and multi-factorial. They exert an intense, wide- 
spectrum anti-inflammatory action and are potent vasoconstrictors. Additionally, they 
regulate the expression of junction proteins in endothelial cells [11,12] and the expression and 
distribution of ion channels and water channels in retinal glial Müller cells (Figure 1A).[13] 
Interestingly, dexamethasone and triamcinolone exert a specific and differential regulation of 
Kir4.1 (K+-inwardly rectifying channel 4.1) and AQP4 (Aquaporin 4) in retinal glial Müller 
cells suggesting that the dose and type of corticosteroid may influence their anti-edematous 
properties.[13] 
Triamcinolone acetonide was the first glucocorticoid injected into the vitreous.[14,15] 
 
The preparations used initially were not developed nor approved for intraocular use, although 
there are now triamcinolone acetonide formulations that are approved for intraocular use. Due 
to its very high hydrophobicity, triamcinolone acetonide forms a solid crystalline aggregate in 
the vitreous, which allows a long-lasting effect. But triamcinolone acetonide was never 
incorporated in a drug delivery system that could provide a controlled release of the drug. 
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Moreover, a potential toxicity of triamcinolone acetonide and of the more hydrophobic 
 
dexamethasone form, has been observed experimentally in vitro and in vivo on retinal and 
vascular cells. After intravitreal administration in healthy rats and in a murine model of 
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choroidal neovascularization, triamcinolone acetonide triggered vascular endothelial cell 
death. It also exerted a deleterious effect on retinal pigmented epithelium and Müller cells via 
a caspase-independent, paraptotic process.[16] The direct application of triamcinolone 
acetonide on rat retinal explants confirmed its toxic effect on vascular endothelial cells 
through caspase-independent mechanisms ,.[17]. Indeed, controversy on the toxicity of 
glucocorticoids on the retina is mostly due to the fact that corticoids can exert toxicity through 
non-classical pathways, undetected by the routinely used toxicology methods [16]. 
Nevertheless, the more hydrophobic forms are the more toxic because their intracellular 
penetration is higher. Clinically, no study was designed to systematically assess the retinal 
safety of triamcinolone acetonide. But several papers reported visual loss after repeated 
intravitreal triamcinolone injections [18] electroretinographic alterations, visual field defects, 
and retinal pigment epithelium changes after accidental subretinal injection [19] or optic 
atrophy after ILM peeling and intravitreal triamcinolone injection [20]. 
Recently, two drug delivery systems have been approved for the sustained intravitreal 
release of glucocorticoids, the dexamethasone (DEX) implant and the fluocinolone acetonide 
(FAc) insert. Along with anti-VEGF agents, they have expanded the toolbox available for 
retina specialists and have revolutionized the management of macular edema. However, none 
of them completely fulfills yet all optimal characteristics required by such therapeutic agents. 
This review will focus on the pharmacological specifications ideally required from such 
devices, the properties of the two approved products, and the clinical evidence regarding their 
therapeutic action and side effects. 
 
 
PHARMACOLOGICAL REQUIREMENTS OF AN IDEAL SUSTAINED- 
RELEASE SYSTEM 
The advantages of drug delivery systems for the sustained release of corticosteroids are: 
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- Controlled and sustained vitreous release of drug for an extended period of time - 
currently three months or more. 
- Reduction of the total administered dose with a potential reduction of ocular side- 
effects 
- Reduction of the frequency and cumulated number of intravitreal injections 
 
- Improved pharmacokinetics with a flattening of concentration peaks and valleys 
 
- Improvement of pharmacodynamics properties resulting from a controlled, stable 
concentration 
 
 
An ideal sustained-release drug delivery system should present the following characteristics: 
 
- Biodegradable matrix with a zero pharmacokinetic order 
 
- Sustained and controlled release lasting for an extended duration 
 
- Complete degradation of the matrix polymer when all the drug is released 
 
- Biocompatibility and ocular tolerance of the matrix materials 
 
- Injectable device, that fits in a small-Gauge needle, typically 23-Gauge or thinner in 
the light of current standards for vitreoretinal procedures 
- Once injected, the implant should induce little or no visual disturbance 
 
- The implant design should allow potential removal in case of excessive side-effects 
 
 
 
EXISTING STEROID SUSTAINED-RELEASE DEVICES 
 
Dexamethasone intravitreal implant 
 
The dexamethasone intravitreal implant (DEX implant, Ozurdex®; Allergan, Inc., 
Irvine, CA) consists of a sustained-release preparation containing 0.7 mg of dexamethasone 
embedded in a biodegradable poly(lactic co-glycolic acid) matrix material (Figures 1B and 
1C). It has been designed to release dexamethasone into the vitreous for up to 6 months, with 
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pharmacokinetics studies confirming the presence of the drug in the retina and vitreous of 
Macaca fascicularis monkeys 6 months after injection, with peak concentrations during the 
first 2 months, and undetectable levels after the 6th month.[21] However, clinical efficacy is 
observed up to 4 months after injection in some eyes.[22] 
 
Dimensions of the DEX implant are: length, 6mm and diameter, 0.46 mm, allowing it to 
fit into a specialized 22-Gauge trans-scleral injector. Intravitreal injection is performed under 
topical anesthetic drops, and the self-sealing incision does not require sutures. 
The DEX implant has been approved by the US Food and Drug Administration (FDA) 
for the following indications: diabetic macular edema (DME), macular edema following 
branch or central retinal vein occlusion and non-infectious posterior uveitis. 
 
 
Sustained-delivery fluocinolone acetonide insert 
 
The sustained-delivery fluocinolone acetonide (FAc) insert (Iluvien®; Alimera  
Sciences, Alpharetta, GA) is composed of nonbiodegradable cylindrical tubes of polymer 
loaded with 0.19 mg of fluocinolone acetonide. Dimensions of the insert are 3.5 × 0.37 mm 
and it is inserted into the vitreous via a 25-Gauge sutureless scleral incision using a 
manufactured injection device (Figures 1 D and 1E). Is has been designed to release FAc at an 
initial rate of 0.25 µg/day. 
Aqueous humor levels of FAc peak during the first 3 months, followed by steady-state 
levels through 36 months.[23] These results are consistent with reports of clinical efficacy for 
up to 3 years post-insertion.[24] 
The FDA approved the FAc insert for the treatment of DME, in patients who have been 
previously treated with a course of corticosteroids and did not have a clinically significant rise 
in intraocular pressure. 
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MAIN OUTCOMES OF CLINICAL TRIALS 
 
For more than two decades from the mid-1980’s, the standard of care for DME had  
been focal or grid laser photocoagulation associated to a strict control of glycemia, blood 
pressure and other cardiovascular comorbidities.[25] Despite its widespread use from the mid- 
2000’s and randomized clinical trials showing that it was beneficial for DME,[26–28] the 
glucocorticoid triamcinolone acetonide was never formulated for intravitreal use specifically 
for DME treatment. Therefore, focal laser photocoagulation remained until recently the only 
approved therapeutic option for DME.[29] In 2012, ranibizumab, an anti-VEGF monoclonal 
antibody fragment, became the first approved drug for the treatment of DME, based on results 
from the RIDE and RISE clinical trials [30,31], and proved superior to triamcinolone 
acetonide.[32] This context explains why controlled, randomized clinical trials evaluating 
steroid-releasing devices have been designed differently according to the selected control 
intervention: sham, laser photocoagulation or anti-VEGF, with some trials also evaluating 
combinations of these treatments. 
 
 
Dexamethasone intravitreal implant 
 
The efficacy of the DEX implant has been assessed by several randomized clinical 
 
trials, which are summarized in Table 1. 
 
In the randomized, masked, phase-III “MEAD” clinical trial that included 377 
participants,1 the 0.7-mg DEX implant was compared to sham over a 3-year period.[33] In a 
third arm, patients received DEX implants at a lower-dose (0.35 mg), but this formulation was 
eventually not retained for commercial distribution and will therefore not be mentioned  
further in this review. Noticeably, inclusion criteria required that baseline visual acuities be 
between 20/200 and 20/50, thus excluding patients with good baseline visual acuity levels 
 
 1 Cohort sizes and results mentioned for all clinical trials will refer to participants who 
completed the study until the end of the follow-up period 
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despite edema (a common finding in DME) and patients with very low baseline levels, who 
have usually less recovery potential. The study was compared of a mixed cohort of treatment- 
naive patients and patients refractory to other therapies. Another specificity of the study  
design was the prohibition of focal laser treatment in the macula in both arms during the study 
period. The mean average reduction in central retinal thickness (measured at the fovea) from 
baseline was greater in the DEX implant group, -112 µm versus -42 µm (p<0.001). The 
percentage of treated patients that had gained ≥15 letters at 3 years was higher than in the 
sham group (22% versus 12%, p=0.018). The mean visual acuity change over the 3-year 
period was only +3.5 letters for DEX-implanted patients, but this difference was significant 
compared to sham (+2.0, p=0.023). Although not clinically meaningful for an individual eye,  
it indicates a favorable distribution of visual acuity gainers over losers among treated patients. 
In addition, 68% of subjects that were phakic at baseline had undergone cataract extraction at 
3 years, versus 20% in the sham group. Noticeably, patients from the DEX group received a 
mean of only 4.1 injections over the 3-year study period. Finally, the rates of dropout or loss 
to follow-up from this study were high (324 subjects out of 701 initially included in the 0.7 
mg DEX and sham arms) and could affect the interpretation of the results. 
Another randomized, double-masked trial compared DEX implant and laser (103 
participants) versus sham and laser (94 participants), with one possible retreatment by 
DEX/sham at 6 or 9 months, and 3 possible additional laser sessions.[34] In the DEX group, a 
significantly greater proportion of subjects had a visual improvement ≥10 letters by 9 months, 
but this effect was not maintained at 12 months, suggesting that retreatment by DEX implant 
should be performed at intervals shorter than 6 months. 
In the head-to-head single-masked, comparative, randomized “BEVORDEX” trial of 
DEX implant (46 subjects) versus the anti-VEGF antibody bevacizumab (42 subjects),[22] 
both treatments achieved to improve visual acuity by 10 letters or more after 12 months in a 
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similar proportion of subjets (40% and 41%, respectively). A greater decrease in central 
macular thickness was observed in the DEX arm (-187 µm versus -122 µm, p=0.015). Yet, 5 
patients from the DEX group had a decrease in visual acuity, versus none from the 
bevacizumab group, a finding explained by the higher rate of cataract development in DEX- 
treated patients. Eventually, a mean of 2.7 DEX-implant injections versus 8.6 bevacizumab 
injections were performed over 12 months. 
Next, a therapy combining bevacizumab at baseline and DEX implant at 1 month plus 
DEX implant re-injection at 5 and 9 months if needed (18 patients) has been evaluated versus 
bevacizumab monthly monotherapy (17 patients), in a randomized, single masked design over 
12 months.[35] There was a significant visual improvement in both groups from baseline but 
no difference in final visual acuities between groups. However, the mean central macular 
thickness reduction was greater in the combination group (−45 µm versus −30 µm p=0.03). In 
this group, the injection sparing effect was limited since patients received an average of 8 
additional injections compared to 9 in the bevacizumab monotherapy group. 
Interestingly, the efficacy of a single DEX implant over a 6-month period has been 
reported in vitrectomized eyes,[36,37] although the absence of vitreous gel may have reduced 
the half-life of the drug within the vitreous cavity. 
 
 
Sustained-delivery fluocinolone acetonide insert 
 
Due to its more recent introduction and the longer study durations required, fewer 
 
studies have evaluated to date the FAc insert as compared to the DEX implant. Randomized 
 
clinical trials evaluating the FAc insert are summarized in Table 2. In the randomized, double 
masked “FAME” trial[24] evaluating the FAc insert (releasing 0.25 µg/day) (209 patients) 
against sham (112 patients), a gain in visual acuity ≥15 letters was observed in 33% of FAc- 
treated subjects compared to 21% of sham-treated subjects after 3 years. Regarding the 
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anatomical response, there was a significant decrease in central retinal thickness in the FAc- 
treated group compared to sham at 1 year, but no significant difference between the groups 
after 3 years. 
A post hoc analysis of the previous study showed that the proportion of patients that 
gained ≥ 15 letters of visual acuity was significantly greater in patients with DME of more than 
3-years duration treated by FAc versus sham, but such a difference was not observed in those 
with DME that lasted less than 3-years at the time of treatment.[38] Other baseline 
characteristics did not differ between both groups. 
 
 
ADVERSE EFFECTS 
 
The most common ocular adverse effects of corticosteroids are secondary cataract 
formation and intraocular pressure rise. Both effects have been observed after topical and 
intraocular corticosteroids administration.[39] 
Despite its frequency, the mechanisms of steroid-induced lens opacification, most 
frequently posterior subcapsular, are not fully understood. It can develop after ocular but also 
systemic steroid treatment, and several possible pathways have been advanced.[40] 
Transcriptional changes may occur in lens epithelial cells, which express the nuclear 
glucocorticoid alpha receptor.[41] An imbalance in intraocular cytokines and growth factors 
affecting the lens homeostasis has also been suggested.[42] 
Corticosteroid-induced ocular hypertension results from an elevated resistance to 
aqueous outflow. Postulated mechanisms include: microsctructural changes in the trabecular 
meshwork, deposition of precipitated substances in the trabecular meshwork and inhibition of 
trabecular phagocytosis by endothelial cells contributing to this accumulation of 
substances.[43] 
Finally, a direct in vitro toxicity of corticosteroids on retinal vascular endothelial cells 
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has been observed via autophagy, caspase-dependent and caspase-independent cell death, and 
direct DNA damage.[17] However, no acute retinal damages have been observed after 
intraocular steroids administration. 
 
 
Dexamethasone intravitreal implant 
 
Variable rates of cataract formation after DEX implant injection have been reported in 
the prospective studies described above, and range from 13% to 50% after 1 year,[22,34,35] 
and 68% after 3 years.[33] In the trial by Boyer et al. with the longest study period, the rate of 
cataract extraction was 59% after 3 years in the DEX implant group versus 7% in the sham 
group. 
In this trial, intraocular pressure rise over 25 mmHg at any visit was observed in 32% of 
patients. Intraocular-pressure-lowering medication was prescribed in 42% of subjects, but 
trabeculectomy was required in only 0.6% of cases. Other trials with follow-up of 1 year 
reported the occurrence of intraocular pressure rise over 25 mmHg in 17-26% of cases.[22,34] 
 
 
Sustained-delivery fluocinolone acetonide insert 
 
In patients who received the FAc insert, cataract formation was observed in 82% over a 
3-year period, with cataract extraction performed in 80% of FAc-implanted subjects versus 
27% of sham-treated subjects.[24] 
Among patients from this prospective cohort, 38% of subjects required intraocular- 
pressure-lowering medication.[24] Incisional glaucoma surgery was performed in 4.8% of 
FAc-treated subjects as compared to 0.5% of sham-treated subjects. Noticeably, the effect of 
FAc on intraocular pressure is likely to be dose-related, since a higher proportion of patients 
receiving the device releasing FAc 0.5µg/day underwent cataract or glaucoma surgery (87% 
and 8%, respectively). 
 
 11 
CONCLUSION 
 
Corticosteroids are among the most widely used classes of drugs in ophthalmology. With the 
advent of sustained-release devices, steroids are now also approved for the treatment of 
macular edema of various origins, including diabetic macular edema. Gluco- and 
mineralocorticoids are expressed in retinal cells and in retinal pigment epithelial cells[44] and 
the expression of these receptors can be modulated in pathological states, as demonstrated in 
animal models[45]. When released in a sustained manner by intravitreal drug delivery 
systems, both dexamethasone and fluocinolone acetonide have a favorable effect on the  
course of diabetic macular edema. Yet, these long-lasting formulations have different 
pharmacological properties and side-effect profiles. These differences can be, in part, 
explained by their different binding affinity to the gluco- and mineralocorticoid receptors, 
subsequently leading to differential transcriptomic effects. Playing with these differential 
affinities, new steroids could be investigated that would optimize the clinical efficacy and 
reduce side-effects. Among future optimization of these devices, the administered dose could 
be adapted to the disease state and a built-in, programmed dose tapering could reduce rebound 
effects. 
These controlled-release ocular drug delivery systems have opened new applications for 
glucosteroids in ophthalmology, even though their mechanisms of action are not fully 
understood. They remain the object of intense investigations, in order to optimize this 
promising treatment strategy and expand it to other causes of macular edema. 
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Figure 1. A. Schematic mechanism of corticosteroid action: after diffusion through the cell 
membrane, corticosteroids bind to the gluco- (GR) and mineralocorticoid receptors (MR) 
according to their affinity profile, and trigger a nuclear displacement of GR- and MR- 
homodimers that regulate the transcription of specific genes involved in the pathogenesis of 
macular edema. B. Injection device for the dexamethasone implant (Ozurdex®). C. 
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Biomicroscropy photograph showing an intravitreal dexamethasone implant. D. Injection 
device for the fluocinolone acetonide insert (Iluvien®). E. Comparative photograph of the 
fluocinolone acetonide insert and a rice grain 
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